Interim Results of Post-Marketing Surveillance Published in International Journal

95.32% Symptom Improvement Among Patients Aged 65 and Older

Safety Evaluated in Patients with Comorbidities and Those on Multiple Medications

A recent study has found that Daewoong Pharmaceutical's gastroesophageal reflux disease (GERD) treatment 'Paxclue' (ingredient: fexuprazan hydrochloride) demonstrated effectiveness in symptom improvement and safety even in real-world clinical settings, including among elderly patients.


On July 3, Daewoong Pharmaceutical announced interim results from the post-marketing surveillance (PMS) for Paxclue, revealing that symptom improvement was confirmed in 95.75% of all patients. The findings were published in 'Gut and Liver,' an SCIE-level international journal in the field of gastroenterology.


Pexuclue 40 mg. Daewoong Pharmaceutical

Pexuclue 40 mg. Daewoong Pharmaceutical

View original image

Unlike strictly controlled clinical trials, this study included elderly patients, patients with comorbidities, and those taking multiple medications, reflecting real-world clinical scenarios. Of the 630 study participants, 46.7% were aged 65 or older, and 14% were 75 or older. Additionally, 71.1% of all patients had comorbid conditions, and 78.6% were taking other medications concurrently.


The research team administered Paxclue 40mg for between 4 and 8 weeks and monitored patient progress, finding that symptoms improved in 95.75% of all patients. In the subgroup of elderly patients aged 65 or older, the symptom improvement rate was 95.32%, similar to the overall patient group.


The quality of life index (GERD-HRQL) improved significantly, dropping from an average of 13.3 points before treatment to 3.0 points after treatment. A lower score on this index indicates less discomfort due to symptoms.


No serious adverse drug reactions were reported in terms of safety. The overall incidence of adverse drug reactions was 2.38%. The company explained that even among patients with hepatic impairment, Paxclue showed consistent efficacy without any drug-related adverse reactions.


Lead researcher Park Muin, professor of gastroenterology at Kosin University Gospel Hospital, commented, "It is significant that we have established clinical evidence supporting the safe and reliable use of this medication, particularly for elderly patients or those with impaired liver function who require special attention in prescribing."



Park Hyungcheol, Head of ETC Marketing Division at Daewoong Pharmaceutical, stated, "This interim PMS analysis demonstrates that Paxclue provides excellent efficacy and high safety even in complex real-world prescribing environments. We will continue to strengthen our medical evidence and enhance our product's competitiveness through ongoing research."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing